c-Met/HGFR
c-Met/HGFR inhibitors target the Hepatocyte Growth Factor Receptor (c-Met), a tyrosine kinase involved in cellular processes such as growth, motility, and morphogenesis. c-Met signaling is implicated in cancer progression, metastasis, and resistance to therapies. Inhibiting c-Met can disrupt tumor growth and spread, making these inhibitors valuable in cancer research. At CymitQuimica, we offer c-Met/HGFR inhibitors to support your research in oncology, metastasis, and targeted cancer therapies.
Found 142 products of "c-Met/HGFR"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
PROTAC c-Met degrader-3
PROTACc-Met degrader-3 (Compound 22b) is a c-Met PROTAC degrader. It facilitates the ubiquitination and degradation of c-Met, with a DC50 of 0.59 nM in EBC-1 cells. PROTACc-Met degrader-3 is applicable in lung cancer research.Formula:C51H54N10O7Color and Shape:SolidMolecular weight:919.037LMTK3-IN-1
CAS:Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.Formula:C18H11F3N4OPurity:99.58%Color and Shape:SoildMolecular weight:356.3Caveolin-1 (82-101) amide (human, mouse, rat)
CAS:Caveolin-1 (82-101) amide (human, mouse, rat), also known as Caveolin-1 scaffolding domain peptide, mitigates aging-related detrimental alterations in variousFormula:C124H170N28O29Purity:98%Color and Shape:SolidMolecular weight:2516.85BMS-777607
CAS:BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3.Formula:C25H19ClF2N4O4Purity:98.16% - 98.56%Color and Shape:SolidMolecular weight:512.89Ref: TM-T2658
2mg59.00€5mg86.00€10mg135.00€25mg251.00€50mg388.00€100mg690.00€200mg1,034.00€500mg1,550.00€c-Met-IN-18
C-Met-IN-18, an ATP-competitive type-III inhibitor, targets both wild-type (WT) and D1228V mutant c-MET with IC50 values of 0.013 µM and 0.20 µM, respectively.Formula:C21H15FN4O2Purity:98%Color and Shape:SolidMolecular weight:374.37c-Met-IN-17
c-Met-IN-17 is a potent inhibitor of c-Met kinase, demonstrating an IC50 of 0.031 μM, and is applicable in anticancer research. [1]Formula:C21H15FN4O2Purity:98%Color and Shape:SolidMolecular weight:374.37c-Met-IN-23
c-Met-IN-23 (Compound 12g) functions as a c-Met inhibitor with an IC50 of 0.052 μM against c-Met. It also inhibits the MDR1 and MRP1/2 pumps in cancerous HepG2 and BxPC3 cells. As such, c-Met-IN-23 serves as an anticancer agent.Formula:C16H13N7OMolecular weight:319.11816PROTAC c-Met degrader-2
CAS:PROTACc-Met degrader-2 (PROTAC2) is a c-Met degrader developed using PROTAC technology, with a DC50 value of 50 nM.Formula:C51H50F2N6O13Color and Shape:SolidMolecular weight:992.97Antitumor agent-111
Antitumor Agent-111 (Compound 46), a c-Met kinase inhibitor (IC50 = 46 nM), exhibits both antitumor and antiproliferative effects.Formula:C34H29ClF2N6O5Purity:98%Color and Shape:SolidMolecular weight:675.08SYN1143
CAS:SYN1143 (AMG-1) strongly inhibits RON & c-Met with IC50s: 9 & 4 nmol/L.Formula:C31H29FN4O5Purity:99.69%Color and Shape:SolidMolecular weight:556.58PF-04217903 methanesulfonate
CAS:PF-04217903 methanesulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).Formula:C20H20N8O4SPurity:98%Color and Shape:SolidMolecular weight:468.49Norleual TFA
Norleual TFA, Ang IV analog, inhibits HGF/c-Met (IC50: 3 pM), blocks AT4, and has strong antiangiogenic effects.Formula:C43H59F3N8O9Molecular weight:888.97S49076
CAS:S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.Formula:C22H22N4O4SPurity:95.35% - 97.4%Color and Shape:SolidMolecular weight:438.5Ref: TM-T3274
1mg34.00€2mg44.00€5mg58.00€10mg93.00€25mg167.00€50mg260.00€100mg432.00€200mg618.00€1mL*10mM (DMSO)64.00€DS-1205
CAS:DS-1205: AXL kinase inhibitor (IC50=1.3 nM), also targets MER, MET, TRKA (IC50s: 63, 104, 407 nM), hinders cell migration and tumor growth.Formula:C41H42FN5O7Purity:99.75%Color and Shape:SolidMolecular weight:735.8Ensartinib hydrochloride
CAS:Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of knownFormula:C26H29Cl4FN6O3Purity:98.73%Color and Shape:SolidMolecular weight:634.36Ref: TM-T22324
1mg54.00€5mg114.00€10mg177.00€25mg356.00€50mg580.00€100mg888.00€1mL*10mM (DMSO)158.00€NVP-BVU972
CAS:NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.Formula:C20H16N6Purity:97.24% - >99.99%Color and Shape:SolidMolecular weight:340.38Ref: TM-T2680
2mg44.00€5mg74.00€10mg97.00€25mg178.00€50mg255.00€100mg359.00€200mg510.00€1mL*10mM (DMSO)84.00€AMG-208
CAS:AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.Formula:C22H17N5O2Purity:98.56%Color and Shape:SolidMolecular weight:383.4Capmatinib 2HCl
CAS:Capmatinib 2HCl (INC-280 2HCl), a c-MET inhibitor, is potent (IC50 = 0.13 nM), highly specific, and induces apoptosis in tumor cells.Formula:C23H19Cl2FN6OPurity:98.80%Color and Shape:SolidMolecular weight:485.34Ref: TM-T4260
2mg34.00€5mg49.00€10mg64.00€25mg84.00€50mg92.00€100mg126.00€500mg303.00€1mL*10mM (DMSO)58.00€Ningetinib
CAS:Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.Formula:C31H29FN4O5Purity:99.95% - 99.98%Color and Shape:SolidMolecular weight:556.58Altiratinib
CAS:Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,Formula:C26H21F3N4O4Purity:99.67% - 99.75%Color and Shape:SolidMolecular weight:510.46
